Patents Examined by Ernst V. Arnold
  • Patent number: 11185607
    Abstract: A preparation method of calcium peroxide-mediated in situ crosslinkable hydrogel as a sustained oxygen-generating matrix, includes: a) reacting a natural or a synthetic polymer with Traut's reagent (TR) in a solvent, and synthesizing a polymer derivative having thiol group in backbone of the polymer derivative; and b) mixing and reacting a solution of the polymer derivative having thiol group with calcium peroxide (CaO2), and thereby forming a hydrogel, wherein in the step b), disulfide bonds (—S—S) are induced between backbones of the polymer derivative having thiol group attached by decomposition of calcium peroxide (CaO2), and thereby in situ crosslinking is formed.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: November 30, 2021
    Assignees: INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Kyung Min Park, Ki Dong Park, Su Jin Park
  • Patent number: 11185508
    Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 30, 2021
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Rosaleen McLaughlin, Adam Parker, Jonathon Whitehouse
  • Patent number: 11179416
    Abstract: The present disclosure relates to manganese dioxide nanoparticles and their use in treatment of oxidative stress and conditions related to or characterized by oxidative stress, including osteoarthritis.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 23, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Blanka Sharma, Isaac Adjei, Shreedevi Kumar
  • Patent number: 11180370
    Abstract: A method of manufacturing the calcium nanohydroxyapatite Ca10(PO4)6(OH)2 structurally modified with Li+ ions (nHAP:Li+) Li0.1Ca9.9(PO4)6(OH)2 optionally doped with 1-2% mol of Eu3+ cations in the form of nanocrystalline powder and use of Li0.1Ca9.9(PO4)6(OH)2 in regenerative medicine as an agent improving of proliferative activity of progenitor cells and demonstrating an anti-apoptotic effect on progenitor cells and in addition use of Li0.1Ca9.9(PO4)6(OH)2 doped with 1-2% mol Eu3+ cations as an agent improving of proliferative activity of progenitor cells and demonstrating the luminescence signal used in diagnostic application.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 23, 2021
    Assignee: INSTYTUT NISKICH TEMPERATUR I BADAN STRUKTURALNYCH PAN IM.W.TRZRBIATOWSKIEGO
    Inventors: Rafal Wiglusz, Krzysztof Marycz
  • Patent number: 11166919
    Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 9, 2021
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse, Adam Parker
  • Patent number: 11160906
    Abstract: The present invention provides a series of injectable bionanocomposites that may be delivered via injection to various tissue repair sites including myocardial infarction, intervertebral disc reconstruction, reconstruction of skeletal muscle, and musculoskeletal applications, urinary incontinence, adipose tissue engineering, and orthopedic applications such as osteoporosis, and meniscus and articular cartilage repair.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: November 2, 2021
    Assignee: The Curators of the University of Missouri
    Inventors: Sheila Ann Grant, David Grant, Daniel Grant
  • Patent number: 11154637
    Abstract: A biodegradable sealant includes: a polyethylene glycol derivative; a photoinitiator; and a solvent, wherein the content of the polyethylene glycol derivative is about 10-75 wt % in the biodegradable sealant. The polyethylene glycol derivative is obtained by a substitution reaction, and in the substitution reaction, the polyethylene glycol is modified with methacrylic anhydride.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: October 26, 2021
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Hsin-Hsin Shen, Yu-Chi Wang, Sen-Lu Chen, Yu-Bing Liou, Jian-Wei Lin, Yi-Hsuan Lee, Ming-Chia Yang, Ying-Wen Shen, Wei-Lin Yu
  • Patent number: 11141380
    Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85 % w/w API particles; 15-30 % w/w coating material coating the API particles; and 3-15 % w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60 % relative humidity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: October 12, 2021
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse
  • Patent number: 11141508
    Abstract: Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: October 12, 2021
    Assignee: Seraxis, Inc.
    Inventor: William L Rust
  • Patent number: 11129774
    Abstract: A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: September 28, 2021
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Cameron Alexander Stewart, Benjamin David Hatton, Yoav Finer
  • Patent number: 11117865
    Abstract: Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.
    Type: Grant
    Filed: June 16, 2019
    Date of Patent: September 14, 2021
    Assignee: Board of Regents, The University Of Texas System
    Inventors: Jia Zhou, Allan R. Brasier, Bing Tian, Zhiqing Liu, Haiying Chen, Erik Rytting
  • Patent number: 11111202
    Abstract: Gamma-butyrolactone (“GBL”) and Gamma-hydroxybutyrate (“GHB”) having a unique carbon footprint as defined by the percent modern carbon (pmc) are described herein. The percent modern carbon can be controlled by varying the amounts of biobased, renewable starting materials and petroleum-based starting materials to prepare GBL or GHB having a defined pmc or by preparing mixtures of GBL or GHB prepared from biobased renewable starting materials and GBL or GHB prepared from petroleum-based starting materials.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: September 7, 2021
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Oliver P. Peoples, Derek Samuelson, Max Senechal, Sung Min Park, Joseph Gredder, Christopher Mirley
  • Patent number: 11103669
    Abstract: A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 31, 2021
    Assignee: Vero Biotech LLC
    Inventor: David H. Fine
  • Patent number: 11103483
    Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 31, 2021
    Assignee: Eagle Pharmaceuticals, Inc.
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 11103490
    Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: August 31, 2021
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Rajeshwar Motheram, Gregory Charles Williams
  • Patent number: 11096829
    Abstract: Systems, methods, and apparatuses for generating and releasing iodine are described. Some embodiments may include a dressing member including a plurality of iodine-forming reagents and a water-swellable material. In some embodiments, the dressing member may include water-swellable fibers. The water-swellable fibers may each include a water-swellable material in which iodine-forming reagents are dispersed. As liquid comes into contact with and is absorbed by the water-swellable material, the iodine-forming reagents may come into contact with each other, causing an iodine-forming reaction to occur, producing iodine.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: August 24, 2021
    Assignee: KCI Licensing, Inc.
    Inventors: Timothy Mark Robinson, Brian Andrews, Christopher Brian Locke
  • Patent number: 11090410
    Abstract: Provided herein are scaffolds and methods useful to promote the formation of functional clusters on a tissue, for example, motor endplates (MEPs) or a component thereof on skeletal muscle cells or tissue, as well as the use of scaffolds so produced for repairing a tissue injury or defect.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: August 17, 2021
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: George J. Christ, Justin M. Saul, John B. Scott, Benjamin T. Corona, Benjamin S. Harrison, Catherine Ward
  • Patent number: 11077067
    Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 3, 2021
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse, Adam Parker
  • Patent number: 11065427
    Abstract: Provided is a method for manufacturing a transdermal absorption sheet which suppresses the cost of manufacturing equipment and prevents deterioration of a pharmaceutical preparation or a raw material thereof, and an intermediate. A mold filled with a first polymer solution is stored in a drying container in an aseptic environment, and the first polymer solution in the mold stored in the drying container is dried outside an aseptic environment. In a case where a surface of the drying container in which the mold is stored is irradiated with an electron beam from an electron beam source, a shield that shields an electron beam is arranged at a position on a straight line connecting the electron beam source and the needle-like recessed portions.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: July 20, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Kenichiro Tamaki, Satoshi Wakamatsu
  • Patent number: 11065188
    Abstract: A dermatological preparation comprises an optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents and the use of said preparation for skin care, hair care, or body care, or dental procedures, or for regenerative medicine such as promoting wound or bone healing. The preparation is formulated to target the hypoxic microenvironment niches of the skin tissue in combination with optimal concentration of nutrients, ions and minerals; to stimulate existing stem cells to trigger the capacity of stem cells to divide and renew and differentiate into specialized cells; and to stimulate molecular and physiological processes, e.g., autophagy, to replenish the substrate pool through the recycling of organelles and the recycling of old damaged proteins and countering free-radical damage to promote anti-aging.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: July 20, 2021
    Assignee: AV Laboratories LLC
    Inventors: Jan Zak, Ami Mezezi, Julian Pino, Nildi Pino